In MDS, the presence of multiple TP53 hits (including multiple mutations, mutation(s) with deletion, or mutation(s) with copy-neutral loss of heterozygosity) predicts a higher risk of transformation into AML, a poorer response to traditional treatments, and inferior survival outcomes [213,214]. This evidence concerns the gene TP53 and myelodysplastic syndrome.